KCAS Bio

KCAS Bio is a global contract research organization (CRO) based in Olathe, Kansas, with over 40 years of experience in bioanalytical and biomarker services. The company supports drug development from early research through commercialization, operating additional facilities in the U.S. and France, and maintaining strategic alliances in Australia. KCAS Bio employs 361 staff and reported $82.5 million in revenue. The company offers a range of services, including bioanalytical, biomarker, immunogenicity, cellular, and molecular assay services, as well as clinical kitting and sample management. KCAS Bio is known for its innovative use of Cytek spectral flow cytometry, which allows for standardized multi-site studies. The company has successfully completed 18 FDA audits without major findings, emphasizing its commitment to regulatory compliance. KCAS Bio has played a role in the development of over 300 FDA-approved drugs and has created more than 5,000 proprietary and non-proprietary assays.